retatrutide weight loss clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide: A Promising Option for
Description
This is a notable savings from what beneficiaries are spending on GLP-1s today
Korner, M., Stockli, M., Waser, B
However, surgery is unlikely to be a feasible population-level solution, due to the nature of complications, limited healthcare capacity and acceptability
And obviously there's outliers and some women are bigger and more muscular
The percentage of adult patients prescribed a GLP-1 drug increased from 2019 to 2024 (Figure 1)
